← Back to directory
Not currently recruitingFunding unknown
- Works count
- 440
- Citation count
- 31,971
- H-index
- 65
- i10-index
- 171
Research interests
Medicine
Biochemistry, Genetics and Molecular Biology
Immunology and Microbiology
Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Cytokine Signaling Pathways and Interactions
Melanoma and MAPK Pathways
Immunotherapy and Immune Responses
Publications
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Science · 2020 · 10.1126/science.abb5920
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
New England Journal of Medicine · 2017 · 10.1056/nejmoa1708539
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2015 · 10.1056/nejmoa1503093
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00083-2
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
New England Journal of Medicine · 2014 · 10.1056/nejmoa1412690
Current projects
No projects listed.